MiR-9 enhances the sensitivity of A549 cells to cisplatin by inhibiting autophagy.
OBJECTIVE
To demonstrate that miR-9 inhibits autophagy by down-regulating Beclin1 and thus enhances the sensitivity of A549 cells to cisplatin.


RESULTS
MiR-9 inhibited Beclin1 expression by binding to its 3'UTR. The inhibition decreased the cisplatin-induced autophagy in A549 cells, evidenced by the decreased expression of LC3II and GFP-LC3 puncta and the increased expression of P62. Upregulation of miR-9 level enhanced the sensibility of A549 cells to cisplatin and increased the cisplatin-induced apoptosis. Overexpression of Beclin1 reversed above effects of miR-9 mimics, cisplatin-induced autophagy was increased and apoptosis was decreased.


CONCLUSIONS
MiR-9 inhibits autophagy via targeting Beclin1 3'UTR and thus enhances cisplatin sensitivity in A549 cells.
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Yan
Y
Zhang
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Xia
X
Meng
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Cheng
C
Li
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Zhoulin
Z
Tan
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Xinwei
X
Guo
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Zhiting
Z
Zhang
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. xitao18@hotmail.com.|Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. xitao18@hotmail.com.
Tao
T
Xi
D000072283:A549 Cells; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001343:Autophagy / Q000187:drug effects*; D000071186:Beclin-1 / Q000096:biosynthesis; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D003432:Cross-Linking Reagents; D004847:Epithelial Cells / Q000187:drug effects*; D015870:Gene Expression; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D011838:Radiation-Sensitizing Agents
D000970:Antineoplastic Agents; C491997:BECN1 protein, human; D000071186:Beclin-1; D003432:Cross-Linking Reagents; C541874:MIRN92 microRNA, human; D035683:MicroRNAs; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin
A549 cells; Apoptosis; Autophagy; Beclin1; Cisplatin; MiR-9